TITLE

Shunt Thrombosis Prevention in Hemodialysis Patients -- A Double-Blind, Randomized Study: Pentoxifylline vs Placebo

AUTHOR(S)
Radmilović, A.; Borić, Z.; Naumović, T.; Stamenković, M.; Muśikić, P.
PUB. DATE
July 1987
SOURCE
Angiology;Jul1987, Vol. 38 Issue 7, p499
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Previous studies demonstrated a high incidence of local thrombosis in patients in whom external arteriovenous shunts were used for vascular access. This procedure provides, therefore, a useful model for the evaluation of potential antithrombotic agents. The effect of the hemorheologically and hemostasiologically active drug Pentoxifylline on the incidence of thrombosis of arteriovenous shunts (Ramires shunt) was investigated in a long-term, double-blind, placebo-controlled study in 51 patients on chronic hemodialysis. The two treatment groups were comparable in age, sex, concomitant medication, and dialysis program (three times per week for four hours). Drugs known to affect platelet function or coagulation were excluded, with the exception of heparin, during the dialysis procedure. All shunts were placed in the forearm and inserted into the distal part of the radial artery and basilic antebrachial vein. Simultaneously, for medical reasons, in all patients an arteriovenous fistula was performed (proximal part of radial artery and cephalic antebrachial vein). Shunt thrombosis was assumed when the flow in the shunt discontinued under visual and auscultatory control. Thrombi were documented by physical removal from the arterial part of the shunt by use of gentle suction or by complete shunt thrombosis (both arterial and venous part of the shunt). Thereafter, the patients' trial period terminated. The total number of thrombi during the observation period was 44 in the pentoxifylline group (26 patients), compared with 82 in the placebo group (25 patients). The mean number of thrombi per patient was 1.69 ± 1.29 in the pentoxifylline group, significantly lower than that in the placebo group (3.28 ± 1.99 / p < 0.05). Further, the periods until the occurrence of first thrombosis (in the arterial part of the shunt) and complete shunt thrombosis were assessed per patient in days: in the pentoxifylline group the first shunt thrombosis occurred after 34.8 ± 6.7 days (&xline; ± s.e.) and with placebo after 16.7 ± 4.4 days (p < 0.05). The complete thrombosis was recorded in the pentoxifylline group after 46.8 ± 6.5 days and with placebo after 24.6 ± 5.8 days (p < 0.05). These findings indicate that pentoxifylline medication markedly reduced the incidence of thrombosis of arteriovenous shunt and distinctly extended the shunt survival period, suggesting an effective antithrombotic property of the drug.
ACCESSION #
16359678

 

Related Articles

  • Treatment of Hemodialysis Access Failure: A Role for Thrombolysis. Sands, Jeffrey J.; Miranda, Carol L. // Clinical & Applied Thrombosis/Hemostasis;Summer1996, Vol. 2 Issue 3, p164 

    Thrombosis of hemodialysis accesses remains a major source of morbidity, hospitalization, and expense for patients with end-stage renal disease. Treatment of hemodialysis accesses includes strategies to prevent access failure and methods for treating acute thromboses. Such techniques as Doppler...

  • Tailoring the initial vascular access for dialysis patients. Konner, Klaus; Hulbert-Shearon, Tempie E.; Roys, Erik C.; Port, Friedrich K. // Kidney International;Jul2002, Vol. 62 Issue 1, p329 

    Tailoring the initial vascular access for dialysis patients. Background. Creating a functioning initial arteriovenous (AV) access for aging and diabetic end-stage renal disease (ESRD) hemodialysis patients has been a challenge. Methods. This study describes 748 consecutive primary AV access...

  • A Preliminary Experience with the Human Homologous Vein Graft for Vascular Access. Gecim, I. E.; Ward, R. G.; Bakran, A.; Aikawa, A.; Sells, R. A. // Vascular Surgery;Sep/Oct1996, Vol. 30 Issue 5, p395 

    In a preliminary study, 38 preserved human homologous saphenous vein grafts were used for secondary vascular access in 36 chronic hemodialysis patients. Cumulative one-year patency was 67%. Twelve grafts failed, 10 owing to thrombosis and 2 owing to infection. Overall complication rate,...

  • Recanalization Occurs in Many Cases of SVS.  // Kidney;Mar/Apr99, Vol. 8 Issue 2, p73 

    Presents an abstract of the study 'Subclavian vascular access stenosis in dialysis patients: Natural history and risk factors,' by D. Hernandez, F. Diaz, M. Rufino, et al.

  • Chronic hemodialysis in infants and children under 2 years of age. Shroff, Rokshana; Wright, Elizabeth; Ledermann, Sarah; Hutchinson, Carol; Rees, Lesley // Pediatric Nephrology;Apr2003, Vol. 18 Issue 4, p378 

    Presents a paper on chronic hemodialysis in infants and children under two years of age. Incidence of problems with vascular access in children; Causes of line infection; Limitations to the effectiveness of chronic hemodialysis.

  • Vascular access use in Europe and the United States: Results from the DOPPS. Pisoni, Ronald L.; Young, Eric W.; Dykstra, Dawn M.; Greenwood, Roger N.; Hecking, Erwin; Gillespie, Brenda; Wolfe, Robert A.; Goodkin, David A.; Held, Philip J. // Kidney International;Jan2002, Vol. 61 Issue 1, p305 

    Vascular access use in Europe and the United States: Results from the DOPPS.. Background: A direct broad-based comparison of vascular access use and survival in Europe (EUR) and the United States (US) has not been performed previously. Case series reports suggest that vascular access practices...

  • Clinical Educators Network nursing recommendations for management of vascular access in hemodialysis patients. Thomas, Alison // CANNT Journal;Jul-Sep2006 Suppleme, Vol. 16, p18 

    A quiz on the management of vascular access in hemodialysis patients is presented.

  • Molecular Therapies for Vascular Access. Lawson, Jeffrey H. // Vascular;Nov2005 Supplement, Vol. 13, pS82 

    The article considers molecular therapies for vascular access. The population of patients in the U.S. requiring hemodialysis for renal replacement therapy, including the annual cost of the procedure is given. It is claimed that access graft failures results in significant morbidity and increased...

  • ANTICOAGULATION ON DIALYSIS.  // Clinical Advisor;Sep2010, Vol. 13 Issue 9, p52 

    The article presents an answer to a question related to ensuring that hemo- or peritoneal dialysis patients maintain therapeutic anticoagulation while on warfarin therapy for deep vein thrombosis (DVT) or hypercoaguable states.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics